Technical Analysis for VTYX - Ventyx Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 0.48% | |
| Inside Day | Range Contraction | 0.48% | |
| 20 DMA Resistance | Bearish | 1.70% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.70% | |
| Inside Day | Range Contraction | 1.70% | |
| Fell Below 20 DMA | Bearish | 2.44% | |
| Wide Range Bar | Range Expansion | 2.44% | |
| Earnings Movers | Other | 2.44% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 17 hours ago |
| Down 1% | about 17 hours ago |
| 20 DMA Resistance | about 17 hours ago |
| Up 3% | about 17 hours ago |
| Up 2% | about 17 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Ventyx Biosciences, Inc. Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Autoimmune Disease Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Autoimmune Disorders Cytokine Lupus Immune Mediated Diseases Molecule Product Psoriatic Arthritis Inflammasome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.5785 |
| 52 Week Low | 1.865 |
| Average Volume | 1,466,746 |
| 200-Day Moving Average | 12.39 |
| 50-Day Moving Average | 5.60 |
| 20-Day Moving Average | 4.33 |
| 10-Day Moving Average | 4.46 |
| Average True Range | 0.45 |
| RSI (14) | 41.52 |
| ADX | 18.41 |
| +DI | 15.43 |
| -DI | 23.84 |
| Chandelier Exit (Long, 3 ATRs) | 3.90 |
| Chandelier Exit (Short, 3 ATRs) | 5.04 |
| Upper Bollinger Bands | 4.96 |
| Lower Bollinger Band | 3.70 |
| Percent B (%b) | 0.39 |
| BandWidth | 29.14 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.28 |
| MACD Histogram | 0.0351 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.55 | ||||
| Resistance 3 (R3) | 4.56 | 4.46 | 4.49 | ||
| Resistance 2 (R2) | 4.46 | 4.36 | 4.45 | 4.47 | |
| Resistance 1 (R1) | 4.32 | 4.31 | 4.27 | 4.31 | 4.45 |
| Pivot Point | 4.22 | 4.22 | 4.19 | 4.21 | 4.22 |
| Support 1 (S1) | 4.08 | 4.12 | 4.03 | 4.07 | 3.93 |
| Support 2 (S2) | 3.98 | 4.07 | 3.97 | 3.91 | |
| Support 3 (S3) | 3.84 | 3.98 | 3.89 | ||
| Support 4 (S4) | 3.83 |
